The human body’s primary defense against diseased cells is a strong immune system, a complex system of cellular level processes that has evolved to both identify and take action against foreign or diseased cells, including cells developing into cancer cells. It is believed that the human body is constantly generating at least some cancer cells, but that the body’s immune system is generally able to handle them. However, a defective immune system, a system compromised by a genetic problem, or environmental factors, or weakened by changes related to the aging process, leaves the body vulnerable to internal or external attack.
For example, it appears that an aging immune system is simply less effective in dealing with cancer cells, although the reasons for this are still not fully understood. As a result, cancer is much more common in people over 60. The immune system must have the ability to both identify and destroy problem cells, and if either of these roles is compromised, the result can be full blown disease.
But science is now learning how to leverage the many remarkable abilities of the human immune system, tweaking it in such a way as to help it identify and then take successful action against cancerous and other corrupted cells. Immunotherapy is just now beginning to appear on the public stage with treatments that partner with the body instead of fighting it.
Advaxis is a clinical-stage biotechnology company developing the next generation of immunotherapies for cancer and infectious diseases. The company’s immunotherapies are based on a novel platform technology involving the use of live, attenuated bacteria that are bio-engineered to secrete antigen/adjuvant fusion protein(s) that redirect the powerful immune response all human beings have to the bacterium to the cancer itself. In effect, the approach puts cancer in the line of fire.
ADXS-HPV, the company’s main anti-cancer drug, is currently being evaluated in 5 clinical trials for HPV-associated diseases, including cervical cancer, head and neck cancer, and anal cancer, and the company has over 15 distinct constructs in various stages of development.
For additional information, visit www.Advaxis.com
About QualityStocks
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to find, evaluate, and learn more about investing in these companies.
Sign up for “The QualityStocks Daily Newsletter” at www.QualityStocks.net
The Quality Stocks Daily Blog http://blog.qualitystocks.net
The Quality Stocks Daily Videos http://videocharts.qualitystocks.net
The Quality Stocks “Ones to Watch” http://gotstocks.qualitystocks.net
Please see disclaimer on the QualityStocks website: http://disclaimer.qualitystocks.net
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment